JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 361, Issue 3, 2000, Pages 298-302

  Invernizzi, Roberto ^a   Garavaglia, Claudio ^a   Samanin, Rosario ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Antipsychotic drugs; Dopamine receptors; Dopamine release; JL13; Microdialysis; Nucleus accumbens; Prefrontal cortex; Striatum

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLORO PYRIDOL[2,3 B][1,5]BENZOXAZEPINE; BENZOXAZINE DERIVATIVE; CLOZAPINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; JL 13; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PSYCHOSIS; RAT; SCHIZOPHRENIA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; RATS;

EID: 0033956720     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900195     Document Type: Article

References (39)

1. 4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 752:26-34
2. Blin O (1999) A comparative review of new antipsychotics. Can J Psychiatry 44:235-244
3. Borison RL (1996) The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 94 [Suppl 389]:5-11
4. Breier A (1999) Cognitive deficits in schizophrenia and its neurochemical basis. Br J Psychiatry 174 [Suppl 37]:16-18
5. 4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic and nigrostriatal dopamine and serotonin release. J Neural Transm 105:749-767
6. Brozoski TJ, Brown RM, Rosvold HE, Goldman-Rakic PS (1979) Cognitive deficits caused by regional depletion of dopamine in the prefrontal cortex of rhesus monkey. Science 205:929-931
7. Bruhwyler J, Liégeois J-F, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Géczy J (1997) JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 36:255-264
8. Gazi L, Bobirnac I, Danzeisen M, Schupbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M, Schoeffter P (1998) The agonist activities of the putative antipsychotic agents L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Br J Pharmacol 124:889-896
9. Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458
10. 2A receptors in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. Mol Brain Res 54:199-211
11. Invernizzi R, Morali F, Pozzi L, Samanin R (1990) Effect of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats. Br J Pharmacol 100:774-778
12. Invernizzi R, Pozzi L, Samanin R (1995) Further studies on the effect of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats. Brain Res 670:165-168
13. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl) 142:78-84
14. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Group (1988) Clozapine for treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
15. Kinon BJ, Lieberman JA (1996) Mechanism of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 124:2-34
16. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54: 567-572
17. Krupp P, Barnes P (1989) Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berl) 99:S118-S121
18. Liégeois J-F, Rogister FA, Bruhwyler J, Damas J, Nguyen TP, Inarejos M-O, Chleide EMG, Mercier MGA, Delarge JE (1994) Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study. J Med Chem 37:519-525
19. Ljungberg T, Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology (Berl) 56:239-247
20. i values. J Pharmacol Exp Ther 251: 238-246
21. 2C) receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955
22. 4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo [2,3b] pyridine) and raclopride. J Pharmacol Exp Ther 287:167-186
23. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
24. 4 receptors in GABAergic neurons of the primate brain. Nature 381:245-248
25. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115:147-156
26. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, Sydney
27. Pazos A, Cortes R, Palacios M (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-249
28. 3H]NGD 94-1. J Pharmacol Exp Ther 282:1020-1027
29. Roberts AC, DeSalvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, Robbins TW (1994) 6-Hydroxydopamine lesion of the prefrontal cortex in monkeys enhances performance on an analogue of the Wisconsin card sort test: possible interactions with subcortical dopamine. J Neurosci 14:2531-2544
30. Robinson TE, Wishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450:209-224
31. 1A receptor activation. Eur J Pharmacol 338:R3-R5
32. Roth BL, Meltzer HY (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1215-1227
33. Saykin AJ, Gur RC, Gur RE, Mozley D, Mozley LH, Resnik SM, Kester B, Stafiniak P (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624
34. 2A antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279
35. 4 receptors in rat forebrain. Neuroreport 8: 3423-3426
36. 2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 156:419-425
37. 4 receptor with high affinity for the antypsychotic clozapine. Nature 350:610-614
38. Watanabe M, Kodama T, Hikosaka K (1997) Increase in extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol 78:2795-2798
39. Weinberger DR, Lipska BK (1995) Cortical maldevelopment, antipsychotic drugs and schizophrenia: a search for a common ground. Schizophr Res 16:87-110